Marek B.
- Country
- Slovakia
- Department
- Outpatient Care of Urology
Research Overview
- Efficacy and Safety of Capivasertib Plus Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial
- Phase 3 Randomized Open-label Study of Opevesostat Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Data & Insights
Has run more than one trial at 9 of 122 partner sites.
Specializations
Prostate Cancer Treatment
This investigator specializes in advanced therapeutic approaches for high-risk prostate cancer, with particular attention to cases following radical prostatectomy and hormone-sensitive manifestations.
- Hormone-Sensitive Prostate Cancer Management
- Post-Prostatectomy Treatment Strategies
- Metastatic Disease Control
Their research encompasses radiotherapy combinations and novel therapeutic agents in prostate cancer treatment.
Molecular Targeting
The investigator focuses on targeted therapeutic approaches, particularly in PTEN-deficient prostate cancers and precision medicine applications in oncology.
- Biomarker-Driven Treatment Selection
- PSMA-PET Guided Therapy
- Molecular Pathway Inhibition
Their work integrates advanced imaging techniques with targeted therapeutic strategies.
Combination Therapies
The investigator explores innovative therapeutic combinations including hormonal therapy with novel agents for prostate cancer treatment.
- Multi-Modal Treatment Approaches
- Novel Drug Combinations
- Hormone Therapy Integration
Their research evaluates the efficacy of combined treatment strategies in advanced prostate cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.